Quiz: Epidemiology and Prognosis in Ovarian Cancer

Article

How much do you know about the epidemiology and prognosis of ovarian cancer? Here's your chance to find out.

In our August ovarian cancer quiz, you’ll get a chance to test your knowledge on the epidemiology and prognosis of this disease. Here’s your first question:

1.  Pain is independently associated with overall survival time among women with recurrent ovarian cancer.

A.True

B.False


12345>>>

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian Cancer
Related Content
Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

Ariana Pelosci
March 18th 2025
Article

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

Rina-S Elicits Encouraging Antitumor Activity in Advanced Ovarian Cancer

Russ Conroy
March 17th 2025
Article

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.

Abemaciclib Plus Hormonal Therapy Shows Promising Efficacy in LGSOC/EEC

Roman Fabbricatore
March 17th 2025
Article

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.